Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins
YaoYao G. Pollock(Johns Hopkins University), Vered Stearns(Johns Hopkins University), Amanda L. Blackford(Johns Hopkins University), Ashley Cimino‐Mathews(Bloomberg (United States)), F. Asrari(Johns Hopkins Hospital), Nancy L. Schoenborn(Johns Hopkins University), Melissa Camp(Johns Hopkins University), Jean L. Wright(University of North Carolina at Chapel Hill), Stacie C. Jeter(Johns Hopkins University), Susan C. Harvey(Johns Hopkins University)
Cited by 17
Related Papers
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
|Journal of Clinical Oncology|2010|800
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
|Journal of Clinical Oncology|2014|795
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751